Hormone replacement therapy in the menopause

A pro opinion

Harriet O. Smith, Dorothy N. Kammerer-Doak, Dorothy M. Barbo, Gloria E. Sarto

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

The preponderance of data support the benefits of HRT in estrogen-deprived and menopausal women to reduce the risks of osteoporosis and cardiovascular disease and to enhance quality of life and life expectancy. Controversies exist with regards to the risk-benefit ratio in women with a history of estrogen-dependent gynecologic tumors or breast cancer. Until these issues are resolved, physicians must carefully weigh, on an individual basis for each patient, the potential risks against the known benefits. Women should be counseled regarding the benefits of exercise, weight control, breast feeding, and cessation of cigarette smoking or excessive alcohol to reduce their risks of cancer, cardiac disease, and/or osteoporosis. HRT is not a panacea for an unhealthy lifestyle. When ERT is contraindicated, viable alternatives to retard bone loss and/or control vasomotor symptoms include calcium supplementation and progestin therapy. The role of tamoxifen as an alternative HRT in women at increased risk for breast cancer development is currently under investigation.

Original languageEnglish (US)
Pages (from-to)343-363
Number of pages21
JournalCa-A Cancer Journal for Clinicians
Volume46
Issue number6
StatePublished - 1996
Externally publishedYes

Fingerprint

Hormone Replacement Therapy
Menopause
Osteoporosis
Estrogens
Breast Neoplasms
Progestins
Tamoxifen
Life Expectancy
Breast Feeding
Life Style
Heart Diseases
Neoplasms
Cardiovascular Diseases
Smoking
Odds Ratio
Alcohols
Quality of Life
Exercise
Calcium
Physicians

ASJC Scopus subject areas

  • Oncology

Cite this

Smith, H. O., Kammerer-Doak, D. N., Barbo, D. M., & Sarto, G. E. (1996). Hormone replacement therapy in the menopause: A pro opinion. Ca-A Cancer Journal for Clinicians, 46(6), 343-363.

Hormone replacement therapy in the menopause : A pro opinion. / Smith, Harriet O.; Kammerer-Doak, Dorothy N.; Barbo, Dorothy M.; Sarto, Gloria E.

In: Ca-A Cancer Journal for Clinicians, Vol. 46, No. 6, 1996, p. 343-363.

Research output: Contribution to journalArticle

Smith, HO, Kammerer-Doak, DN, Barbo, DM & Sarto, GE 1996, 'Hormone replacement therapy in the menopause: A pro opinion', Ca-A Cancer Journal for Clinicians, vol. 46, no. 6, pp. 343-363.
Smith, Harriet O. ; Kammerer-Doak, Dorothy N. ; Barbo, Dorothy M. ; Sarto, Gloria E. / Hormone replacement therapy in the menopause : A pro opinion. In: Ca-A Cancer Journal for Clinicians. 1996 ; Vol. 46, No. 6. pp. 343-363.
@article{4a53d204c1544ea6be4626aaf5fe308d,
title = "Hormone replacement therapy in the menopause: A pro opinion",
abstract = "The preponderance of data support the benefits of HRT in estrogen-deprived and menopausal women to reduce the risks of osteoporosis and cardiovascular disease and to enhance quality of life and life expectancy. Controversies exist with regards to the risk-benefit ratio in women with a history of estrogen-dependent gynecologic tumors or breast cancer. Until these issues are resolved, physicians must carefully weigh, on an individual basis for each patient, the potential risks against the known benefits. Women should be counseled regarding the benefits of exercise, weight control, breast feeding, and cessation of cigarette smoking or excessive alcohol to reduce their risks of cancer, cardiac disease, and/or osteoporosis. HRT is not a panacea for an unhealthy lifestyle. When ERT is contraindicated, viable alternatives to retard bone loss and/or control vasomotor symptoms include calcium supplementation and progestin therapy. The role of tamoxifen as an alternative HRT in women at increased risk for breast cancer development is currently under investigation.",
author = "Smith, {Harriet O.} and Kammerer-Doak, {Dorothy N.} and Barbo, {Dorothy M.} and Sarto, {Gloria E.}",
year = "1996",
language = "English (US)",
volume = "46",
pages = "343--363",
journal = "Ca-A Cancer Journal for Clinicians",
issn = "0007-9235",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Hormone replacement therapy in the menopause

T2 - A pro opinion

AU - Smith, Harriet O.

AU - Kammerer-Doak, Dorothy N.

AU - Barbo, Dorothy M.

AU - Sarto, Gloria E.

PY - 1996

Y1 - 1996

N2 - The preponderance of data support the benefits of HRT in estrogen-deprived and menopausal women to reduce the risks of osteoporosis and cardiovascular disease and to enhance quality of life and life expectancy. Controversies exist with regards to the risk-benefit ratio in women with a history of estrogen-dependent gynecologic tumors or breast cancer. Until these issues are resolved, physicians must carefully weigh, on an individual basis for each patient, the potential risks against the known benefits. Women should be counseled regarding the benefits of exercise, weight control, breast feeding, and cessation of cigarette smoking or excessive alcohol to reduce their risks of cancer, cardiac disease, and/or osteoporosis. HRT is not a panacea for an unhealthy lifestyle. When ERT is contraindicated, viable alternatives to retard bone loss and/or control vasomotor symptoms include calcium supplementation and progestin therapy. The role of tamoxifen as an alternative HRT in women at increased risk for breast cancer development is currently under investigation.

AB - The preponderance of data support the benefits of HRT in estrogen-deprived and menopausal women to reduce the risks of osteoporosis and cardiovascular disease and to enhance quality of life and life expectancy. Controversies exist with regards to the risk-benefit ratio in women with a history of estrogen-dependent gynecologic tumors or breast cancer. Until these issues are resolved, physicians must carefully weigh, on an individual basis for each patient, the potential risks against the known benefits. Women should be counseled regarding the benefits of exercise, weight control, breast feeding, and cessation of cigarette smoking or excessive alcohol to reduce their risks of cancer, cardiac disease, and/or osteoporosis. HRT is not a panacea for an unhealthy lifestyle. When ERT is contraindicated, viable alternatives to retard bone loss and/or control vasomotor symptoms include calcium supplementation and progestin therapy. The role of tamoxifen as an alternative HRT in women at increased risk for breast cancer development is currently under investigation.

UR - http://www.scopus.com/inward/record.url?scp=0029846094&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029846094&partnerID=8YFLogxK

M3 - Article

VL - 46

SP - 343

EP - 363

JO - Ca-A Cancer Journal for Clinicians

JF - Ca-A Cancer Journal for Clinicians

SN - 0007-9235

IS - 6

ER -